Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey. more
Time Frame | URGN | Sector | S&P500 |
---|---|---|---|
1-Week Return | -5.9% | -3.39% | 0.2% |
1-Month Return | 2.63% | -1.92% | 2.72% |
3-Month Return | -11.76% | -10.54% | 7.31% |
6-Month Return | -38.02% | -4.47% | 10.44% |
1-Year Return | -24.52% | 4.06% | 27.53% |
3-Year Return | 16.68% | 0.94% | 30.88% |
5-Year Return | -65.02% | 36.67% | 89.21% |
10-Year Return | -18.96% | 102.87% | 199.95% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 18.00K | 11.80M | 48.04M | 64.36M | 82.71M | [{"date":"2019-12-31","value":0.02,"profit":true},{"date":"2020-12-31","value":14.26,"profit":true},{"date":"2021-12-31","value":58.08,"profit":true},{"date":"2022-12-31","value":77.81,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 48.00K | 1.01M | 5.16M | 7.65M | 9.36M | [{"date":"2019-12-31","value":0.51,"profit":true},{"date":"2020-12-31","value":10.78,"profit":true},{"date":"2021-12-31","value":55.09,"profit":true},{"date":"2022-12-31","value":81.76,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | 18.00K | 10.79M | 42.88M | 56.70M | 73.35M | [{"date":"2019-12-31","value":0.02,"profit":true},{"date":"2020-12-31","value":14.71,"profit":true},{"date":"2021-12-31","value":58.46,"profit":true},{"date":"2022-12-31","value":77.3,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | 100.00% | 91.45% | 89.27% | 88.11% | 88.68% | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":91.45,"profit":true},{"date":"2021-12-31","value":89.27,"profit":true},{"date":"2022-12-31","value":88.11,"profit":true},{"date":"2023-12-31","value":88.68,"profit":true}] |
Operating Expenses | 109.50M | 137.53M | 135.18M | 135.74M | 138.89M | [{"date":"2019-12-31","value":78.84,"profit":true},{"date":"2020-12-31","value":99.02,"profit":true},{"date":"2021-12-31","value":97.33,"profit":true},{"date":"2022-12-31","value":97.74,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (109.48M) | (126.74M) | (92.29M) | (79.04M) | (65.54M) | [{"date":"2019-12-31","value":-10947800000,"profit":false},{"date":"2020-12-31","value":-12673900000,"profit":false},{"date":"2021-12-31","value":-9229200000,"profit":false},{"date":"2022-12-31","value":-7904100000,"profit":false},{"date":"2023-12-31","value":-6553600000,"profit":false}] |
Total Non-Operating Income/Expense | 8.95M | 3.26M | (16.87M) | (36.41M) | (44.68M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":36.41,"profit":true},{"date":"2021-12-31","value":-188.5,"profit":false},{"date":"2022-12-31","value":-406.96,"profit":false},{"date":"2023-12-31","value":-499.37,"profit":false}] |
Pre-Tax Income | (105.15M) | (125.11M) | (109.37M) | (108.03M) | (98.32M) | [{"date":"2019-12-31","value":-10514600000,"profit":false},{"date":"2020-12-31","value":-12511000000,"profit":false},{"date":"2021-12-31","value":-10937100000,"profit":false},{"date":"2022-12-31","value":-10802800000,"profit":false},{"date":"2023-12-31","value":-9832400000,"profit":false}] |
Income Taxes | (4.62M) | 3.37M | 1.45M | 1.14M | 3.92M | [{"date":"2019-12-31","value":-117.76,"profit":false},{"date":"2020-12-31","value":86.07,"profit":true},{"date":"2021-12-31","value":36.96,"profit":true},{"date":"2022-12-31","value":28.95,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Income After Taxes | (100.53M) | (128.48M) | (110.82M) | (109.16M) | (102.24M) | [{"date":"2019-12-31","value":-10053000000,"profit":false},{"date":"2020-12-31","value":-12848400000,"profit":false},{"date":"2021-12-31","value":-11082000000,"profit":false},{"date":"2022-12-31","value":-10916300000,"profit":false},{"date":"2023-12-31","value":-10224400000,"profit":false}] |
Income From Continuous Operations | (105.15M) | (128.48M) | (110.82M) | (109.78M) | (105.10M) | [{"date":"2019-12-31","value":-10514600000,"profit":false},{"date":"2020-12-31","value":-12848400000,"profit":false},{"date":"2021-12-31","value":-11082000000,"profit":false},{"date":"2022-12-31","value":-10978300000,"profit":false},{"date":"2023-12-31","value":-10509700000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (100.53M) | (128.48M) | (110.82M) | (109.16M) | (102.24M) | [{"date":"2019-12-31","value":-10053000000,"profit":false},{"date":"2020-12-31","value":-12848400000,"profit":false},{"date":"2021-12-31","value":-11082000000,"profit":false},{"date":"2022-12-31","value":-10916300000,"profit":false},{"date":"2023-12-31","value":-10224400000,"profit":false}] |
EPS (Diluted) | (5.11) | (5.92) | (4.96) | (4.78) | (3.73) | [{"date":"2019-12-31","value":-511,"profit":false},{"date":"2020-12-31","value":-592,"profit":false},{"date":"2021-12-31","value":-496,"profit":false},{"date":"2022-12-31","value":-478,"profit":false},{"date":"2023-12-31","value":-373,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
URGN | |
---|---|
Cash Ratio | 7.61 |
Current Ratio | 9.00 |
Quick Ratio | 8.77 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
URGN | |
---|---|
ROA (LTM) | -21.12% |
ROE (LTM) | -1481.26% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
URGN | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.92 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.08 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
URGN | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 5.35 |
P/B | 18.74 |
Price/FCF | NM |
EV/R | 3.92 |
EV/Ebitda | NM |
PEG | NM |
UroGen Pharma Ltd (URGN) share price today is $10.707
Yes, Indians can buy shares of UroGen Pharma Ltd (URGN) on Vested. To buy UroGen Pharma Ltd from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in URGN stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of UroGen Pharma Ltd (URGN) via the Vested app. You can start investing in UroGen Pharma Ltd (URGN) with a minimum investment of $1.
You can invest in shares of UroGen Pharma Ltd (URGN) via Vested in three simple steps:
The 52-week high price of UroGen Pharma Ltd (URGN) is $20.7. The 52-week low price of UroGen Pharma Ltd (URGN) is $10.6.
The price-to-earnings (P/E) ratio of UroGen Pharma Ltd (URGN) is
The price-to-book (P/B) ratio of UroGen Pharma Ltd (URGN) is 18.74
The dividend yield of UroGen Pharma Ltd (URGN) is 0.00%
The market capitalization of UroGen Pharma Ltd (URGN) is $478.12M
The stock symbol (or ticker) of UroGen Pharma Ltd is URGN